Compare Tango Therapeutics Inc. (TNGX) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Health Care Select Sector SPDR Fund — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B), while Health Care Select Sector SPDR Fund trades at $176.22 (market cap $44.49B). The key difference: Health Care Select Sector SPDR Fund is far larger — about 11.9× Tango Therapeutics Inc.'s market cap, and Health Care Select Sector SPDR Fund is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Health Care Select Sector SPDR Fund for 100 Days on average.
| TNGX | XLV | |
|---|---|---|
Market Cap | $3.75B | $44.49B |
Volume | 9,619,106 | 8,745,019 |
Sector | Health | — |
52-Week High | $32.90 | $175.68 |
52-Week Low | $7.50 | $142.33 |
Typical Hold Time | 0 Days | 100 Days |
Enterprise Value | $2.77B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
XLV trades at $169.66, down 1.35% on the day, while maintaining a bullish technical outlook with strong moving average support. The healthcare ETF's low 0.08% expense ratio and diversified exposure to 60 S&P 500 healthcare stocks provide cost-effective sector access. Recent news highlights XLV's defensive characteristics during potential Fed rate hikes and its competitive positioning against peer healthcare ETFs.
The ETF offers defensive growth exposure with healthcare sector stability, though elevated RSI levels suggest near-term consolidation. Political volatility and pharmaceutical trial failures present sector-specific risks, while XLV's technical strength and institutional interest support continued upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
